How much postmenopause weight gain can be blamed on weight-promoting medications?

July 15, 2020

CLEVELAND, Ohio (July 15, 2020)--Abdominal weight gain, which is common during the postmenopause period, is associated with an array of health problems, including diabetes and heart disease. A new study suggests that the use of antidepressants, beta-blockers, and insulin during the menopause transition is partially to blame for such unhealthy weight gain. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).

Many medications prescribed for hypertension, diabetes, depression, and/or other mental health problems are associated with unintentional weight gain. Unfortunately, postmenopausal women, who already have a high prevalence of being overweight or obese, are more likely to be treated with weight-promoting medications for these various health problems at the time of the menopause transition. In this new study based on data collected from women who participated in the Women's Health Initiative, researchers sought to quantify the magnitude of the association between weight-promoting medications and a 3-year weight change in postmenopausal women.

The study measured body mass index (BMI) and waist circumference at baseline and at 3 years and cross-checked the results with an inventory of prescribed medicines, including antidepressants, beta-blockers, insulin, and/or glucocorticosteroids. On the basis of these results, the researchers concluded that taking at least one weight-promoting medication was associated with a greater increase in BMI and waist circumference compared with women not on these medications. Both of these measurements increased with the number of weight-promoting drugs prescribed. Those who took either antidepressants or insulin, or a combination of antidepressants and beta-blockers, were most likely to have a significant increase in BMI compared with nonusers. Racial and ethnic minority women--groups with a higher weight at baseline--also were more susceptible to weight gain associated with the use of prescription medications.

In response to the study's results, the researchers suggest a need for healthcare providers to be more vigilant when prescribing various medications to postmenopausal women. Specifically, healthcare providers need to determine whether various medications are absolutely necessary, whether alternative options are available, and whether the lowest dose is being prescribed to provide the desired results.

Study results appear in the article "The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative."

"This study highlights the significant adverse health effects of obesity and the association between use of weight-promoting medications such as antidepressants, antihypertensives, and insulin and weight gain in midlife women. In addition to ensuring that these weight-promoting medications are used judiciously and in the lowest doses needed to achieve the desired outcomes, lifestyle strategies to mitigate these adverse effects, such as diet quality, physical activity level, and sleep quality and duration, should be emphasized," says Dr. Stephanie Faubion, NAMS medical director.
-end-
The authors have prepared a video summary of this study that can be found at http://links.lww.com/MENO/A617.

For more information about menopause and healthy aging, visit http://www.menopause.org.

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit http://www.menopause.org.

The North American Menopause Society (NAMS)

Related Diabetes Articles from Brightsurf:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.